| Title |
Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia
|
|---|---|
| Published in |
Current Neurology and Neuroscience Reports, July 2012
|
| DOI | 10.1007/s11910-012-0290-7 |
| Pubmed ID | |
| Authors |
D. Aarsland, C. Ballard, A. Rongve, M. Broadstock, P. Svenningsson |
| Abstract |
Despite the frequency and importance of dementia associated with Parkinson's disease (PDD) and dementia with Lewy bodies (DLB), there is relatively little evidence on which to base treatment. Evidence from meta-analysis suggests that rivastigmine can improve cognition and functioning in PDD and also reduce risk of falling. There is also evidence supporting its use in DLB. Recent evidence suggests that memantine may also be effective, particularly for PDD, although evidence is more conflicting. Memantine may also improve parkinsonism and dyskinesias. Few clinical trials of cognition in PD without dementia exist, but there is preliminary evidence for atomoxetine, memantine, and piribedil. There is a lack of systematic evidence for the treatment of visual hallucinations and depression in PDD and DLB. In addition, there is a need for studies of whether potentially disease-modifying agents can prevent or delay the progression to dementia in PD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Belgium | 1 | <1% |
| Unknown | 106 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 15% |
| Researcher | 15 | 14% |
| Student > Bachelor | 12 | 11% |
| Student > Postgraduate | 10 | 9% |
| Student > Ph. D. Student | 10 | 9% |
| Other | 20 | 18% |
| Unknown | 26 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 35% |
| Psychology | 16 | 15% |
| Neuroscience | 11 | 10% |
| Agricultural and Biological Sciences | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 6 | 6% |
| Unknown | 28 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2012.
All research outputs
#18,314,922
of 22,678,224 outputs
Outputs from Current Neurology and Neuroscience Reports
#760
of 913 outputs
Outputs of similar age
#125,716
of 163,891 outputs
Outputs of similar age from Current Neurology and Neuroscience Reports
#15
of 18 outputs
Altmetric has tracked 22,678,224 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 913 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,891 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.